1. Introduction 1.1 Market Definition 2. Research Methodology 3. Executive Summary 4. Key Inferences 5. Human Recombinant Insulin Market Overview 5.1 Current Market Scenario 5.2 Porters Five Forces 5.2.1 Bargaining Power of Suppliers 5.2.2 Bargaining Power of Consumers 5.2.3 Threat of New Entrants 5.2.4 Threat of Substitute Product and Services 5.2.5 Competitive Rivalry within the Industry 6. Human Recombinant Insulin Market Dynamics 6.1 Market Driver 6.1.1 Increasing Prevalence of Diabetes around the World 6.1.2 Increasing Investments in Diabetes Research Activities 6.2 Market Restraint 6.2.1 Risks Associated with Recombinant Insulin 6.2.2 High Cost of Recombinant Insulin 6.3 Opportunities 6.4 Key Challenges 7. Human Recombinant Insulin Market Segmentation 7.1 By Product Type 7.1.1 Short-Acting Human Insulin 7.1.2 Intermediate-Acting Human Insulin 7.1.3 Premixed Human Insulin 7.2 By Brand 7.2.1 Insuman 7.2.2 Humulin 7.2.3 Novolin 7.2.4 Others 7.3 By Distribution Channel 7.3.1 Hospital Pharmacies 7.3.2 Retail Pharmacies 7.3.3 Online Pharmacies 7.4 By Geography 7.4.1 North America Human Recombinant Insulin Market (2018-2023) 7.4.1.1 United States Human Recombinant Insulin Market (2018-2023) 7.4.1.2 Canada Human Recombinant Insulin Market (2018-2023) 7.4.1.3 Mexico Human Recombinant Insulin Market (2018-2023) 7.4.2 Europe Human Recombinant Insulin Market (2018-2023) 7.4.2.1 France Human Recombinant Insulin Market (2018-2023) 7.4.2.2 Germany Human Recombinant Insulin Market (2018-2023) 7.4.2.3 United Kingdom Human Recombinant Insulin Market (2018-2023) 7.4.2.4 Italy Human Recombinant Insulin Market (2018-2023) 7.4.2.5 Spain Human Recombinant Insulin Market (2018-2023) 7.4.2.6 Rest of Europe 7.4.3 Asia-Pacific Human Recombinant Insulin Market (2018-2023) 7.4.3.1 China Human Recombinant Insulin Market (2018-2023) 7.4.3.2 Japan Human Recombinant Insulin Market (2018-2023) 7.4.3.3 India Human Recombinant Insulin Market (2018-2023) 7.4.3.4 Australia & New Zealand Human Recombinant Insulin Market (2018-2023) 7.4.3.5 South Korea Human Recombinant Insulin Market (2018-2023) 7.4.3.6 Rest of Asia-Pacific 7.4.4 Middle East & Africa Human Recombinant Insulin Market (2018-2023) 7.4.4.1 GCC Human Recombinant Insulin Market (2018-2023) 7.4.4.2 South Africa Human Recombinant Insulin Market (2018-2023) 7.4.4.3 Rest of Middle East & Africa 7.4.5 South America Human Recombinant Insulin Market (2018-2023) 7.4.5.1 Brazil Human Recombinant Insulin Market (2018-2023) 7.4.5.2 Argentina Human Recombinant Insulin Market (2018-2023) 7.4.5.3 Rest of South America 8. Company Profiles & Competitive Landscape 8.1 Biocon 8.2 Bioton S.A. 8.3 Eli Lilly and Company 8.4 Gan & Lee Pharmaceuticals, Ltd. 8.5 Julphar Gulf Pharmaceutical Industries 8.6 Novo Nordisk A/S 8.7 Sanofi S.A. 8.8 Zhuhai United Laboratories Co., Ltd. *List Not Exhaustive 9. Future of the Human Recombinant Insulin Market

Biocon, Bioton S.A., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Ltd., Julphar Gulf Pharmaceutical Industries, Novo Nordisk A/S, Sanofi S.A., and Zhuhai United Laboratories Co., ltd